Prognostic Significance of Transforming Growth Factor β Receptor II in Estrogen Receptor-Negative Breast Cancer Patients

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 491-498

  Buck, Miriam B ^a,b   Fritz, Peter ^a   Dippon, Juergen ^c   Zugmaier, Gerhard ^d   Knabbe, Cornelius ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0842333147     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0320-03     Document Type: Article

References (41)

1. Souhami, R. L., Tannock, I., Hohenberger, P., and Horiot, J. C. Oxford Textbook of Oncology. Oxford: New York Oxford University Press, 2002.
2. Knabbe, C., Lippman, M. E., Wakefield, L. M., Flanders, K. C., Kasid, A., Derynck, R., and Dickson, R. B. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48: 417-428, 1987.
3. Knabbe, C., Zugmaier, G., Schmahl, M., Dietel, M., Lippman, M. E., and Dickson, R. B. Induction of transforming growth factor β by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am. J. Clin. Oncol., 14: S15-S20, 1991.
4. Knabbe, C., Kopp, A., Hilgers, W., Lang, D., Muller, V., Zugmaier, G., and Jonat, W. Regulation and role of TGF β production in breast cancer. Ann. N. Y. Acad. Sci., 784: 263-276, 1996.
5. Muller, V., Jensen, E. V., and Knabbe, C. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res., 58: 263-267, 1998.
6. Kopp, A., Jonat, W., Schmahl, M., and Knabbe, C. Transforming growth factor β 2 (TGF-β 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res., 55: 4512-4515, 1995.
7. Roberts, A. B. Molecular and cell biology of TGF-β. Miner. Electrolyte Metab., 24: 111-119, 1998.
8. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. Mechanism of activation of the TGF-β receptor. Nature (Lond.), 370: 341-347, 1994.
9. Buck, M., von der Fecht, J., and Knabbe, C. Antiestrogenic regulation of transforming growth factor β receptors I and II in human breast cancer cells. Ann. N. Y. Acad. Sci., 963: 140-143, 2002.
10. Basolo, F., Fiore, L., Ciardiello, F., Calvo, S., Fontanini, G., Conaldi, P. G., and Toniolo, A. Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor β 1 (TGF-β 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Int. J. Cancer, 56: 736-742, 1994.
11. Zugmaier, G., Ennis, B. W., Deschauer, B., Katz, D., Knabbe, C., Wilding, G., Daly, P., Lippman, M. E., and Dickson, R. B. Transforming growth factors type β 1 and β 2 are equipotent growth inhibitors of human breast cancer cell lines. J. Cell Physiol., 141: 353-361, 1989.
12. Gorsch, S. M., Memoli, V. A., Stukel, T. A., Gold, L. I., and Arrick, B. A. Immunohistochemical staining for transforming growth factor β 1 associates with disease progression in human breast cancer. Cancer Res., 52: 6949-6952, 1992.
13. McEarchern, J. A., Kobie, J. J., Mack, V., Wu, R. S., Meade-Tollin, L., Arteaga, C. L., Dumont, N., Besselsen, D., Seftor, E., Hendrix, M. J., Katsanis, E., and Akporiaye, E. T. Invasion and metastasis of a mammary tumor involves TGF-β signaling. Int. J. Cancer, 91: 76-82, 2001.
14. Kalkhoven, E., Roelen, B. A., de Winter, J. P., Mummery, C. L., van den Eijnden-van Raaij, A. J., van der Saag, P. T., and van der Burg, B. Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ., 6: 1151-1161, 1995.
15. Laiho, M., Weis, M. B., and Massague, J. Concomitant loss of transforming growth factor (TGF)-β receptor types I and II in TGF-β-resistant cell mutants implicates both receptor types in signal transduction. J. Biol. Chem., 265: 18518-18524, 1990.
16. Chen, C. R., Kang, Y., and Massague, J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor β growth arrest program. Proc. Natl. Acad. Sci. USA, 98: 992-999, 2001.
17. Xie, W., Mertens, J. C., Reiss, D. J., Rimm, D. L., Camp, R. L., Haffty, B. G., and Reiss, M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res., 62: 497-505, 2002.
18. TNM Classification of Malignant Tumors, 5 edition: J. Wiley & Sons, New York, 1997.
19. Fritz, P., Murdter, T. E., Eichelbaum, M., Siegle, I. I., Weissert, M., and Zanger, U. M. Microsomal epoxide hydrolase expression as a predictor of tamoxifen response in primary breast cancer: a retrospective exploratory study with long-term follow-up. J. Clin. Oncol., 19: 3-9, 2001.
20. Zwaagstra, J. C., Guimond, A., and O'Connor-McCourt, M. D. Predominant intracellular localization of the type I transforming growth factor-β receptor and increased nuclear accumulation after growth arrest. Exp. Cell Res., 258: 121-134, 2000.
21. Gobbi, H., Arteaga, C. L., Jensen, R. A., Simpson, J. F., Dupont, W. D., Olson, S. J., Schuyler, P. A., Plummer, W. D., Jr., and Page, D. L. Loss of expression of transforming growth factor β type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology, 36: 168-177, 2000.
22. Gobbi, H., Dupont, W. D., Simpson, J. F., Plummer, W. D., Jr., Schuyler, P. A., Olson, S. J., Arteaga, C. L., and Page, D. L. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl. Cancer Inst., 91: 2096-2101, 1999.
23. Guo, Y., and Kyprianou, N. Overexpression of transforming growth factor (TGF) β1 type 11 receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ., 9: 185-193, 1998.
24. Schaller, G., Evers, K., Papadopoulos, S., Ebert, A., and Buhler, H. Current use of HER2 tests. Ann. Oncol., 12 (Suppl. 1): S97-S100, 2001.
25. Kim, I. Y., Ahn, H. J., Zelner, D. J., Shaw, J. W., Lang, S., Kato, M., Oefelein, M. G., Miyazono, K., Nemeth, J. A., Kozlowski, J. M., and Lee, C. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res., 2: 1255-1261, 1996.
26. Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L., and Arteaga, C. L. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem., 275: 36803-36810, 2000.
27. Frey, R. S., and Mulder, K. M. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. Cancer Res., 57: 628-633, 1997.
28. Hanafusa, H., Ninomiya-Tsuji, J., Masuyama, N., Nishita, M., Fujisawa, J., Shibuya, H., Matsumoto, K., and Nishida, E. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J. Biol. Chem., 274: 27161-27167, 1999.
29. Heldin, C. H., Miyazono, K., and ten Dijke, P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature (Lond.), 390: 465-471, 1997.
30. Petritsch, C., Beug, H., Balmain, A., and Oft, M. TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev., 14: 3093-3101, 2000.
31. Wagner, M., Kleeff, J., Friess, H., Buchler, M. W., and Korc, M. Enhanced expression of the type II transforming growth factor-β receptor is associated with decreased survival in human pancreatic cancer. Pancreas, 19: 370-376, 1999.
32. Matsushita, M., Matsuzaki, K., Date, M., Watanabe, T., Shibano, K., Nakagawa, T., Yanagitani, S., Amoh, Y., Takemoto, H., Ogata, N., Yamamoto, C., Kubota, Y., Seki, T., Inokuchi, H., Nishizawa, M., Takada, H., Sawamura, T., Okamura, A., and Inoue, K. Down-regulation of TGF-β receptors in human colorectal cancer: implications for cancer development. Br. J. Cancer, 80: 194-205, 1999.
33. Wang, J., Han, W., Zborowska, E., Liang, J., Wang, X., Willson, J. K. V., Sun, L., and Brattain, M. G. Reduced expression of transforming growth factor β type 1 receptor contributes to the malignancy of human colon carcinoma cells. J. Biol. Chem., 271: 17366-17371, 1996.
34. Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., Koteliansky, V., and Arteaga, C. L. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Investig., 109: 1551-1559, 2002.
35. Welch, D. R., Fabra, A., and Nakajima, M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl. Acad. Sci. USA, 87: 7678-7682, 1990.
36. Oft, M., Heider, K. H., and Beug, H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr. Biol., 8: 1243-1252, 1998.
37. Anbazhagan, R., Bornman, D. M., Johnston, J. C., Westra, W. H., and Gabrielson, E. The S387Y mutations of the transforming growth factor-β receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma. Cancer Res., 59: 3363-3364, 1999.
38. Lucke, C. D., Philpott, A., Metcalfe, J. C., Thompson, A. M., Hughes-Davies, L., Kemp, P. R., and Hesketh, R. Inhibiting mutations in the transforming growth factor β type 2 receptor in recurrent human breast cancer. Cancer Res., 61: 482-485, 2001.
39. Curtis, S. W., Washburn, T., Sewall, C., DiAugustine, R., Lindzey, J., Couse, J. F., and Korach, K. S. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knock-out mice lack estrogen-like response to epidermal growth factor. Proc. Natl. Acad. Sci. USA, 93: 12626-12630, 1996.
40. Ignar-Trowbridge, D. M., Nelson, K. G., Bidwell, M. C., Curtis, S. W., Washburn, T. F., McLachlan, J. A., and Korach, K. S. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA, 89: 4658-4662, 1992.
41. Matsuda, T., Yamamoto, T., Muraguchi, A., and Saatcioglu, F. Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J. Biol. Chem., 276: 42908-42914, 2001.